IAS Guidelines 1
An update of the guidelines developed by expert panels commissioned by the International AIDS Society – USA was published in the August 2006 edition of the Journal of the American Medical Association (JAMA). The recommendations of the panel centered on four key issues: when to start antiretroviral therapy; what to start with; when to change; and what to change to.
New IAS guidelines suggest Invirase/r has a lower lipid profile
- The recommended initial regimen remains a combination of two nRTIs with either an NNRTI or a PI boosted with low-dose ritonavir.
- Among boosted PIs, SQV/r, LPV/r, FPV/r and ATV/r are equally recommended.
- The choice of agent for treatment-naïve patients will depends on the individual patient profile and factors such as pill burden and adverse event profiles which impact on patient adherence.
- Hyperlipidaemia, lipodystrophy and insulin resistance are listed as adverse events with Kaletra.
- The guidelines suggest Invirase/r has lower lipid effects
IAS guidelines recommends < 50 copies/ml as goal of therapy even for heavily treatment-experienced patients
- The guidelines recommend that, even for heavily treatment-experienced patients, the goal of therapy should be to reduce HIV viral load to below 50 copies/ml.
- New agents, tipranavir and darunavir are reviewed, with particular attention to the high percentage of patients achieving undetectable viral loads when given in combination with FUZEON.
- The new IAS guidelines acknowledge the contribution that FUZEON made in both the RESIST and POWER trials stating that both these studies have helped define the optimal time in which to use FUZEON.
1. Hammer SM, et al. JAMA 2006; 296: 827-843.
These guidelines are available online at:
http://jama.ama-assn.org/cgi/content/full/296/7/827